2016 Annual Report and Accounts and notice of AGM
Tiziana Life Sciences plc
("Tiziana" or "the Company")
2016 Annual Report and Accounts and notice of Annual General Meeting
London, 01 June 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that further to the Company's announcement of its annual results on 23 May 2017, copies of the Annual Report and Accounts for the financial year ended 31 December 2016 and the Notice of Annual General Meeting of the Company (the "Shareholder Documents") are now available via the Company's website at www.tizianalifesciences.com/investor-relations and from the Company's registered office at 3rd Floor, 11-12 St James's Square, London SW1Y 4LB.
Hard copy versions of the above Shareholder Documents have today been posted to shareholders who have elected to receive them in paper form.
The Company's Annual General Meeting will be held at 10.30 a.m. on Thursday 29 June 2017 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.
For more information go to http://www.tizianalifesciences.com
Contacts
|
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder
|
+44 (0)20 7493 2853 |
|
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner
|
+44 (0)20 7213 0880 |
|
Beaufort Securities Limited (Broker) Saif Janjua
|
+44 (0)20 7382 8300 |
|
FTI Consulting Simon Conway / Natalie Garland-Collins |
+44 (0)20 3727 1000 |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.